| Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble AC Stelzer, AT Frank, JD Kratz, MD Swanson, MJ Gonzalez-Hernandez, ... Nature chemical biology 7 (8), 553-559, 2011 | 298 | 2011 |
| RNA dynamics by design: biasing ensembles towards the ligand-bound state AC Stelzer, JD Kratz, Q Zhang, HM Al-Hashimi Angewandte Chemie (International ed. in English) 49 (33), 5731, 2010 | 61 | 2010 |
| Esophagogastric cancers: integrating immunotherapy therapy into current practice MA Patel, JD Kratz, SJ Lubner, NK Loconte, NV Uboha Journal of Clinical Oncology 40 (24), 2751, 2022 | 34 | 2022 |
| Targeted therapy in metastatic colorectal cancer: current standards and novel agents in review RA DeStefanis, JD Kratz, PB Emmerich, DA Deming Current colorectal cancer reports 15, 61-69, 2019 | 33 | 2019 |
| MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers SL Fricke, SN Payne, PF Favreau, JD Kratz, CA Pasch, TM Foley, ... Molecular cancer therapeutics 18 (2), 346-355, 2019 | 27 | 2019 |
| The multidisciplinary management of colorectal cancer: present and future paradigms CK Sievers, JD Kratz, LD Zurbriggen, NK LoConte, SJ Lubner, N Uboha, ... Clinics in colon and rectal surgery 29 (03), 232-238, 2016 | 26 | 2016 |
| Atherosclerosis and nanotechnology: diagnostic and therapeutic applications JD Kratz, A Chaddha, S Bhattacharjee, SN Goonewardena Cardiovascular drugs and therapy 30, 33-39, 2016 | 24 | 2016 |
| Design considerations for PAMAM dendrimer therapeutics SN Goonewardena, JD Kratz, H Zong, AM Desai, S Tang, S Emery, ... Bioorganic & medicinal chemistry letters 23 (10), 2872-2875, 2013 | 19 | 2013 |
| Technologies to assess drug response and heterogeneity in patient-derived cancer organoids MC Skala, DA Deming, JD Kratz Annual review of biomedical engineering 24, 157-177, 2022 | 13 | 2022 |
| Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ … NV Uboha, JC Eickhoff, JD Maloney, D McCarthy, M DeCamp, ... Journal of Clinical Oncology 40 (16_suppl), 4034-4034, 2022 | 11 | 2022 |
| Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity RA DeStefanis, JD Kratz, AM Olson, A Sunil, AK DeZeeuw, AA Gillette, ... Scientific Reports 12 (1), 5205, 2022 | 10 | 2022 |
| Human Colon Organoids and other laboratory strategies to enhance patient treatment selection KA Johnson, RA DeStefanis, PB Emmerich, PT Grogan, JD Kratz, ... Current treatment options in oncology 21, 1-15, 2020 | 8 | 2020 |
| Incorporating genomics into the care of patients with advanced breast cancer J Kratz, M Burkard, T O’Meara, L Pusztai, Z Veitch, PL Bedard American Society of Clinical Oncology Educational Book 38, 56-64, 2018 | 8 | 2018 |
| Metastatic bulk independently predicts outcomes for EGFR precision targeting in colorectal cancer JD Kratz, NV Uboha, SJ Lubner, DL Mulkerin, L Clipson, Y Yi, M Yu, ... Journal of the National Comprehensive Cancer Network 16 (12), 1442-1450, 2018 | 6 | 2018 |
| Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis JD Kratz, AY El-Shazly, SG Mambuque, E Demetria, P Veldkamp, ... Malawi Medical Journal 28 (4), 185-187, 2016 | 5 | 2016 |
| Integrating subclonal response heterogeneity to define cancer organoid therapeutic sensitivity JD Kratz, S Rehman, KA Johnson, AA Gillette, A Sunil, PF Favreau, ... bioRxiv, 2021.10. 15.464556, 2021 | 4 | 2021 |
| Etiologies of patient-derived colorectal cancer organoid growth heterogeneity across multiple patient samples and culture conditions A Sunil, JD Kratz, SK Makkar, S Rehman, AA Gillette, KA Johnson, ... Cancer Research 80 (16_Supplement), 1494-1494, 2020 | 2 | 2020 |
| Molecular Targets and Therapies for Ampullary Cancer MA Patel, JD Kratz, AS Carlson, YO Ascencio, BS Kelley, NK LoConte Journal of the National Comprehensive Cancer Network 1 (aop), 1-8, 2024 | 1 | 2024 |
| CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma M Nukaya, C Cafferty, K Zahed, I Yun, DP Al-Adra, NA Kazim, AR Farghli, ... bioRxiv, 2023.04. 22.537934, 2023 | 1 | 2023 |
| Immunotherapy for HCC: limitations in patients with NASH PD Agarwal, MR Lucey, A Said, J Kratz Annals of Hepatology 28 (2), 100886, 2023 | 1 | 2023 |
